IN2015DN01616A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01616A
IN2015DN01616A IN1616DEN2015A IN2015DN01616A IN 2015DN01616 A IN2015DN01616 A IN 2015DN01616A IN 1616DEN2015 A IN1616DEN2015 A IN 1616DEN2015A IN 2015DN01616 A IN2015DN01616 A IN 2015DN01616A
Authority
IN
India
Prior art keywords
tissue
cells
cell formulation
myocardial
pluripotent stem
Prior art date
Application number
Inventor
Masanori Yoshida
Shinya Minatoguchi
Mari Dezawa
Original Assignee
Clio Inc
Univ Gifu
Univ Tohoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clio Inc, Univ Gifu, Univ Tohoku filed Critical Clio Inc
Publication of IN2015DN01616A publication Critical patent/IN2015DN01616A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells

Abstract

The purpose of the present invention is to provide a new medical application using pluripotent stem cells (Muse cells) for regenerative medicine. The present invention provides a cell formulation for treating myocardial infarctions especially severe large scale myocardial infarctions and accompanying heart failure. Said cell formulation contains SSEA3 positive pluripotent stem cells isolated from either mesenchymal tissue from an organism or cultured mesenchymal cells. This cell formulation is based on the following myocardial tissue regeneration mechanism: intravenous administration of Muse cells to subjects with the abovementioned disorders results in said Muse cells selectively accumulating in the damaged myocardial tissue and within said tissue differentiating into cardiac muscle.
IN1616DEN2015 2012-08-17 2013-08-15 IN2015DN01616A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012181029 2012-08-17
PCT/JP2013/054049 WO2014027474A1 (en) 2012-08-17 2013-02-19 Pluripotent stem cell that induces repair and regeneration after myocardial infarction
PCT/JP2013/071981 WO2014027684A1 (en) 2012-08-17 2013-08-15 Pluripotent stem cell that induces repair and regeneration after myocardial infarction

Publications (1)

Publication Number Publication Date
IN2015DN01616A true IN2015DN01616A (en) 2015-07-03

Family

ID=50685515

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1616DEN2015 IN2015DN01616A (en) 2012-08-17 2013-08-15

Country Status (14)

Country Link
US (3) US9844570B2 (en)
EP (2) EP2886123B1 (en)
JP (1) JP5968442B2 (en)
KR (1) KR101730052B1 (en)
CN (1) CN104582711B (en)
AU (1) AU2013303492B2 (en)
CA (1) CA2882239C (en)
DK (1) DK2886123T3 (en)
ES (1) ES2767182T3 (en)
IN (1) IN2015DN01616A (en)
PL (1) PL2886123T3 (en)
PT (1) PT2886123T (en)
SG (2) SG10201800829XA (en)
WO (2) WO2014027474A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014027474A1 (en) 2012-08-17 2014-02-20 株式会社Ｃｌｉｏ Pluripotent stem cell that induces repair and regeneration after myocardial infarction
JP2015160820A (en) * 2014-02-26 2015-09-07 株式会社Ｃｌｉｏ Pluripotent stem cell for treating chronic renal damage
JP6452107B2 (en) 2014-09-05 2019-01-16 国立大学法人 東京大学 Pluripotent stem cells for the treatment of diabetic skin ulcers
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration
JP6770673B2 (en) * 2016-02-26 2020-10-21 国立大学法人東海国立大学機構 Prognostic markers for acute myocardial infarction and their use
CN109689073A (en) * 2016-07-01 2019-04-26 国立大学法人东北大学 The prevention of organ fibrosis or therapeutic agent
JP7029729B2 (en) * 2016-07-29 2022-03-04 国立大学法人東北大学 Preventive or therapeutic agents for vascular disorders
US11920180B2 (en) 2016-08-03 2024-03-05 Tohoku University Method for inducing differentiation of pluripotent stem cells in vitro
AU2017305067B2 (en) * 2016-08-03 2022-11-03 Hiroshi Yabuki Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
US20190240262A1 (en) * 2016-08-03 2019-08-08 National University Corporation Nagoya University Amelioration and treatment of chronic lung disease using pluripotent stem cells
CN106822899B (en) * 2017-03-10 2020-11-27 北京大学 Medicine for promoting myocardial regeneration by inhibiting autophagy
SG11202003507QA (en) * 2017-10-17 2020-05-28 Univ Hiroshima Pluripotent stem cells inducing osteochondral repair
JP7102666B2 (en) * 2018-01-25 2022-07-20 国立大学法人東海国立大学機構 Use for Muse cell mobilizers and myocardial damage
JP7072777B2 (en) * 2018-07-03 2022-05-23 株式会社生命科学インスティテュート Pluripotent stem cells for the treatment of chronic nephropathy
CN110302212A (en) * 2019-07-17 2019-10-08 陶正博 A kind of cell preparation and preparation method thereof for treating acute myocardial infarction AMI
WO2021033247A1 (en) 2019-08-19 2021-02-25 セルアクシア株式会社 Cell-containing pharmaceutical composition
CA3153237A1 (en) * 2019-09-05 2021-03-11 Tohoku University Therapeutic agent for myocarditis
US20220387507A1 (en) * 2019-10-31 2022-12-08 Life Science Institute, Inc. Therapy for interstitial cystitis by pluripotent stem cells
WO2021201286A1 (en) 2020-04-02 2021-10-07 国立大学法人東北大学 High-potential pluripotent stem cells
JP2021073305A (en) * 2021-02-09 2021-05-13 株式会社生命科学インスティテュート Pluripotent stem cells for treating chronic kidney disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000484A1 (en) * 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
EP1007631B2 (en) * 1997-07-14 2009-02-18 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
WO2000006701A1 (en) * 1998-07-31 2000-02-10 Genzyme Corporation Improvement of cardiac function by mesenchymal stem cell transplantation
WO2002009650A2 (en) 2000-07-31 2002-02-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002057430A2 (en) * 2001-01-20 2002-07-25 Cardion Ag Pluripotent adult stem cells derived from regenerative tissue
IL159580A0 (en) 2001-07-12 2004-06-01 Geron Corp Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
US9782439B2 (en) 2005-01-27 2017-10-10 Japan Health Sciences Foundation Cell sheet containing mesenchymal stem cells
ZA200804673B (en) 2005-12-13 2009-11-25 Univ Kyoto Nuclear reprogramming factor
CN101517069A (en) * 2006-07-13 2009-08-26 塞拉帝思股份公司 A novel population of multipotent cardiac precursor cells derived from human blastocysts derived stem cells
EP2205251B1 (en) 2007-10-01 2017-01-11 University of Miami A method to amplify cardiac stem cells in vitro and in vivo
WO2009057537A1 (en) 2007-11-02 2009-05-07 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
JP5564679B2 (en) 2009-04-16 2014-07-30 公益財団法人ヒューマンサイエンス振興財団 Cardiomyocyte differentiation induction promoter and method of use thereof
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
AU2011317203B2 (en) * 2010-10-18 2016-10-20 Sunshine Life Science & Technology Corp. Human multipotent embryonic stem cell-like progenitor cells
WO2014027474A1 (en) 2012-08-17 2014-02-20 株式会社Ｃｌｉｏ Pluripotent stem cell that induces repair and regeneration after myocardial infarction

Also Published As

Publication number Publication date
EP3659612B1 (en) 2023-06-07
CA2882239A1 (en) 2014-02-20
CA2882239C (en) 2018-05-22
CN104582711B (en) 2019-12-06
AU2013303492A1 (en) 2015-03-12
US9844570B2 (en) 2017-12-19
US10639335B2 (en) 2020-05-05
US20190307806A1 (en) 2019-10-10
WO2014027684A1 (en) 2014-02-20
EP2886123A4 (en) 2016-06-22
EP2886123A1 (en) 2015-06-24
DK2886123T3 (en) 2020-01-27
EP3659612A1 (en) 2020-06-03
US20150196600A1 (en) 2015-07-16
PL2886123T3 (en) 2020-05-18
PT2886123T (en) 2020-01-22
WO2014027474A1 (en) 2014-02-20
JPWO2014027684A1 (en) 2016-07-28
CN104582711A (en) 2015-04-29
US10376544B2 (en) 2019-08-13
SG11201501185WA (en) 2015-05-28
JP5968442B2 (en) 2016-08-10
SG10201800829XA (en) 2018-03-28
AU2013303492B2 (en) 2017-02-16
KR101730052B1 (en) 2017-04-25
US20180050067A1 (en) 2018-02-22
ES2767182T3 (en) 2020-06-16
KR20150043482A (en) 2015-04-22
EP2886123B1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
IN2015DN01616A (en)
NZ623454A (en) Pharmaceutical composition for the treatment of heart diseases
MX2016005574A (en) Nicotinamide riboside compositions for topical use in treating skin conditions.
BR122020000182B1 (en) Midbrain dopaminergic neurons for engraftment
MX340275B (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders.
ES2721180T3 (en) Therapeutic products using fat cells and cell secretions
MX2013002381A (en) Bone marrow derived cd271 precursor cells for cardiac repair.
WO2012106367A3 (en) Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
JP2014509319A5 (en)
Vawda et al. Current stem cell treatments for spinal cord injury
EA201490995A1 (en) USE OF FO-TI TO ENHANCE MOBILIZATION AND PROLIFERATION OF STEM CELLS
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
WO2014183033A3 (en) G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal
Zhang et al. Effects of Rehmannia glutinosa oligosaccharide on human adipose-derived mesenchymal stem cells in vitro
Gui-xian et al. Therapeutic effects of umbilical cord mesenchymal stem cells transplantation on systemic lupus erythematosus
WO2014072720A3 (en) Cell differentiation
Pompei et al. Cyanidin reduces preadipocyte differentiation and relative ChREBP expression
SG11201810188VA (en) Amelioration and treatment of perinatal brain damage with pluripotent stem cells
SG11201900983TA (en) Amelioration and treatment of chronic lung disease using pluripotent stem cells
WO2012169897A8 (en) Weight reducing material
WO2014063035A3 (en) Treatment of pain using amnion derived adherent cells
Belicchi et al. Impact of Muscular Dystrophy on the Regenerative Properties of interstitial Muscle Cells
Lange-Consiglio et al. In vitro immunomodulatory activity of conditioned medium obtained from amnion-derived horse progenitor cells and its first clinical application in horse tendon injuries
PL418104A1 (en) Method for tissue regeneration using the regenerating tissues
Mishima et al. Serious Hypocalcemia After Withdrawal of Vitamin D Analog in Bedridden Nonagenarians with Previous Thyroidectomy: A Report of Two Cases.